Migration through basement membrane modulates eosinophil expression of CD44.
BACKGROUND
Tissue eosinophils express more membrane receptors and release more mediators than blood eosinophils, suggesting that migration from blood to tissue modulates eosinophil phenotype and functions.


OBJECTIVE
We postulated that eosinophil passage through endothelial basement membrane, an important step of eosinophil migration into tissue, may be responsible for some of these changes.


METHODS
We previously showed that 5-oxo-6, 8, 11, 14-eicosatetraenoic acid (5-oxo-ETE) in combination with IL-5 promotes eosinophil migration through Matrigel, a mouse tumour cell-derived basement membrane. Using this model, we evaluated the effect of trans-Matrigel migration on purified human blood eosinophil expressions of CD44, CD69 and HLA-DR that either increase or appear on activated eosinophils, and releases of peroxidase (EPO), leukotriene (LT) C(4) and granulocyte-monocyte colony stimulating factor (GM-CSF).


RESULTS
IL-5, but not 5-oxo-ETE, increased eosinophil expression of CD44 and CD69. Migration of eosinophils through Matrigel significantly increased CD44 expression level over the one induced by IL-5 (P = 0.0001). Migration through Matrigel did not modify CD69 expression compared with the one obtained in the presence of IL-5 alone; however, incubation of eosinophils on Matrigel decreased IL-5-induced CD69 (P = 0.0001). Trans-Matrigel migration did not modify HLA-DR expression, nor EPO, LTC(4) and GM-CSF releases.


CONCLUSIONS
These data show that in vitro trans-Matrigel migration and Matrigel contact modulate eosinophil membrane receptor expression. Consequently, they suggest that migration through basement membrane mediates changes in cell-surface phenotype observed on activated eosinophils and probably prepares them for interactions with tissue components and cells.
Dallaire
M-J
MJ
Unité de Recherche en Pneumologie, Centre de Recherche de Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval, Sainte-Foy, Québec, Canada.
Ferland
C
C
Lavigne
S
S
Chakir
J
J
Laviolette
M
M
D000293:Adolescent; D000328:Adult; D001095:Arachidonic Acids / Q000494:pharmacology; D001249:Asthma / Q000378:metabolism / Q000503:physiopathology; D001485:Basement Membrane / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D001672:Biocompatible Materials / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D003094:Collagen / Q000494:pharmacology; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D004338:Drug Combinations; D004804:Eosinophils / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis* / Q000187:drug effects; D018836:Inflammation Mediators / Q000378:metabolism; D015848:Interleukin-5 / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011509:Proteoglycans / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000187:drug effects
D001095:Arachidonic Acids; D001672:Biocompatible Materials; D016207:Cytokines; D004338:Drug Combinations; D018960:Hyaluronan Receptors; D018836:Inflammation Mediators; D015848:Interleukin-5; D007797:Laminin; D011509:Proteoglycans; D011956:Receptors, Cell Surface; C059485:matrigel; C080828:5-oxo-6,8,11,14-eicosatetraenoic acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003094:Collagen